PD-L1表达联合肿瘤浸润淋巴细胞特征与转移性黑色素瘤生存及治疗结局的关联
该回顾性研究纳入51例接受免疫检查点抑制剂(ICI)和54例接受非ICI治疗的转移性黑色素瘤患者,评估PD-L1表达≥5%联合CD8、CD28、Ki67等TIL特征与总生存(OS)的关联。结果显示PD-L1与CD8单独分析均与OS或免疫治疗反应无显著关联,但联合分析中PD-L1-/CD8+状态与全人群及非ICI亚组OS延长显著相关,PD-L1+/CD8+状态在ICI组为良好预后因素而在非ICI组为不良预后因素。
要点
- PD-L1单独或CD8单独与OS及免疫治疗反应无显著关联。
- 原发灶PD-L1-/CD8+状态与全人群及非ICI亚组OS延长显著相关。
- PD-L1+/CD8+在ICI组为良好预后因素,在非ICI组为不良预后因素。
核心结论
- 治疗前PD-L1表达联合CD8+ TIL水平可更好地评估转移性黑色素瘤患者接受免疫治疗或其他方案的总生存并预测治疗反应。
研究设计与样本
- 回顾性研究,纳入51例接受ICI治疗和54例接受非ICI治疗的转移性黑色素瘤患者,评估PD-L1表达≥5%联合TIL特征(CD8、CD28、Ki67)与OS的关联。
主要发现
- PD-L1阳性在原发黑色素瘤和配对转移灶中分别占33%和39%,但原发灶与配对转移灶间一致性差(κ=0.283)。
- PD-L1表达与CD8+ TIL作为单一标志物分析时,与OS或免疫治疗反应无显著关联。
- 原发黑色素瘤样本联合分析显示,PD-L1-/CD8+状态与全人群OS延长显著相关(P=0.04),在非ICI亚组亦显著(P=0.009)。
- PD-L1+/CD8+状态在ICI治疗患者中为良好预后因素(P=0.022),在非ICI治疗患者中与不良预后显著相关(P=0.014)。
- CD28表达与结局无关,而Ki67表达在CD8+ TIL+/PD-L1-亚组中与较差OS显著相关(P=0.02)。
关键数值与推荐
- PD-L1阳性定义为肿瘤细胞PD-L1表达≥5%。
- 原发灶与配对转移灶PD-L1一致性κ=0.283。
- PD-L1-/CD8+与OS延长相关:全人群P=0.04,非ICI亚组P=0.009。
- PD-L1+/CD8+与OS相关:ICI组P=0.022(良好预后),非ICI组P=0.014(不良预后)。
- CD8+ TIL+/PD-L1-亚组中Ki67表达与较差OS相关(P=0.02)。
临床怎么用
- 治疗前可联合检测原发黑色素瘤PD-L1表达与CD8+ TIL水平,辅助评估转移性黑色素瘤患者预后及治疗反应。
- PD-L1+/CD8+状态提示ICI治疗可能获益,而PD-L1-/CD8+状态在非ICI治疗中与较好生存相关。
- CD8+ TIL+/PD-L1-亚组中Ki67高表达提示预后较差,需更密切随访。
局限性
- 回顾性研究,样本量有限(ICI组51例,非ICI组54例)。
- 原发灶与配对转移灶PD-L1表达一致性差,可能影响检测部位的选取。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent advances obtained with immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1) protein have significantly improved the outcome of patients with metastatic melanoma. The PD-L1 expression in tumour cells as detected by immunohistochemistry is a predictive biomarker in some solid tumours, but appears insufficient as prognostic or predictive factor of response to ICIs in metastatic melanomas. OBJECTIVES: We investigated whether the presence and the features of pretreatment CD8+ tumour-infiltrating T lymphocytes (TILs) could be a complementary prognostic or predictive biomarker in patients with metastatic melanoma. METHODS: In this retrospective study, we evaluated the association of PD-L1 expression ≥5% of tumour cells combined with TIL features (CD8, CD28, Ki67) with the overall survival (OS) among 51 patients treated with ICIs and 54 patients treated with other treatment options (non-ICIs). RESULTS: PD-L1 positivity was observed in 33% and 39% of primary melanomas and matched metastases, respectively, with, however, poor concordance between the primary and the matched metastatic site (κ = 0.283). No significant association was noted between PD-L1 expression and CD8+ TIL profile analysed as single markers and OS or response to immunotherapy. Instead, their combined analysis in primary melanoma samples showed that the PD-L1-/CD8+ status was significantly associated with prolonged OS in the whole population (P = 0.04) and in the subgroup treated with non-ICIs (P = 0.009). Conversely, the PD-L1+/CD8+ status was a good prognostic factor in patients treated with ICIs (P = 0.022), whereas was significantly associated with poor prognosis in patients treated with non-ICIs (P = 0.014). While the expression of CD28 was not related to outcome, the Ki67 expression was significantly associated with poor OS in the subgroup CD8+ TIL+/PD-L1- (P = 0.02). CONCLUSIONS: The pretreatment combination of PD-L1 expression with the level of CD8+ TILs could better assess OS and predict therapeutic response of patients with metastatic melanoma treated by either immunotherapy or other treatment regimens.
引用
- Bence C, Hofman V, Chamorey E, et al. Association of combined PD-L1 expression and tumour-infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. J Eur Acad Dermatol Venereol. 2019. PMID: 31625630. doi:10.1111/jdv.16016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。